News - Biotechnology, Licensing, Anti-Arthritics/Rheumatics

Celgene gains rights to Nogra product in potential $1 billion-plus deal

Celgene gains rights to Nogra product in potential $1 billion-plus deal

24-04-2014

US biotech firm Celgene has entered a global license agreement with privately-held Irish company Nogra…

Anti-Arthritics/RheumaticsBiotechnologyCelgeneGED-0301LicensingNogra Pharma

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

04-04-2014

World leading independent biotech firm Amgen revealed in a Securities and Exchange Commission filing…

AmgenAnti-Arthritics/RheumaticsBiotechnologyGlaxoSmithKlineLicensingProliaXgeva

SOBI restructures Kineret and Kepivance deals

09-09-2013

Swedish Orphan Biovitrum (STO: SOBI) said this morning that it has acquired the full rights to develop…

AmgenAnti-Arthritics/RheumaticsBiotechnologyKepivanceKineretLicensingOncologyPharmaceuticalRare diseasesSwedish Orphan Biovitrum

Baxter and Coherus in up to $246 million deal for biosimilar etanercept

04-09-2013

US companies Baxter International (NYSE:BAX) and Coherus Biosciences have entered into an exclusive collaboration…

AmgenAnti-Arthritics/RheumaticsBaxter InternationalBiotechnologyCoherus BioSciencesEnbreletanerceptGenericsLicensingResearch

Bristol-Myers and Simcere agree to co-develop/commercialize Orencia SC in China

14-06-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) and China-based Simcere Pharmaceutical (NYSE: SCR) have…

Anti-Arthritics/RheumaticsAsia-PacificBiotechnologyBristol-Myers SquibbLicensingOrenciaPharmaceuticalSimcere Pharmaceutical

Neovacs moving forward in rheumatoid arthritis, say analysts

17-05-2013

French biotech firm Neovacs (Alternext Paris: ALNEV) intends to initiate a Phase IIb trial with its lead…

Anti-Arthritics/RheumaticsBiotechnologyFinancialLicensingNeovacsResearch

Unigene and Nordic Bioscience amend JDV accord; Amgen Vectibix China deal

10-05-2013

USA-based Unigene Laboratories (PINK: UGNE) has entered into an equity transfer and exclusive license…

AmgenAnti-Arthritics/RheumaticsBiotechnologyDiabetesLicensingMergers & AcquisitionsNordic BioscienceOncologyPharmaceuticalUGP302Unigene LabsVectibixZhejiang Beta Pharma

Concert Pharma in $300 million-plus deal with Celgene

07-05-2013

Privately-held biotech firm Concert Pharmaceuticals said yesterday (May 6) that it has entered into a…

Anti-Arthritics/RheumaticsapremilastBiotechnologyCelgeneConcert PharmaceuticalsInflammatory diseasesLicensingOncologyResearch

Phenex in up to $135 million research collaboration with Janssen

17-12-2012

Privately-held German drug discovery firm Phenex Pharmaceuticals has entered into an agreement with Janssen…

Anti-Arthritics/RheumaticsBiotechnologyGastro-intestinalsInflammatory diseasesJanssenJohnson & JohnsonLicensingPhenex PharmaceuticalsResearch

Merck & Co in Nanobody deal with Ablynx; J&J and Astellas join forces on RA

02-10-2012

US pharma giant Merck & Co (NYSE: MRK) has entered into a collaboration with Belgium's Ablynx (Euronext…

AblynxAnti-Arthritics/RheumaticsASPO15KAstellas PharmaBiotechnologyJohnson & JohnsonLicensingMerck & CoPharmaceutical

AstraZeneca collaborates with Amgen on five MAbs

03-04-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and Amgen (Nasdaq: AMGN), the world's largest independent…

AmgenAnti-Arthritics/RheumaticsAstraZenecaBiotechnologybrodalumabInflammatory diseasesLicensingPharmaceutical

Galapagos leaps on $1.35 billion RA drug deal with Abbott Labs

01-03-2012

Belgian drug developer Galapagos (Euronext: GLPG) saw its shares rocket 27% to a record high 13.89 euros…

Abbott LaboratoriesAnti-Arthritics/RheumaticsBiotechnologyGalapagosLicensingPharmaceutical

Nektar sells Cimzia and Mircera royalty rights for $124 million

01-03-2012

US biotech firm Nektar Therapeutics (Nasdaq: NKTR) has agreed to sell to Royalty Pharma its royalties…

Anti-Arthritics/RheumaticsBiotechnologyLicensingNephrology and Hepatology

GSK exercises option for Galapagos drug candidates

21-02-2012

Belgium-based Galapagos NV (Euronext: GLPG) says that its partner, UK pharma giant GlaxoSmithKline (LSE:…

Anti-Arthritics/RheumaticsBiotechnologyGalapagosGlaxoSmithKlineInflammatory diseasesLicensingPharmaceuticalResearch

Abbott in further deal with Reata

12-12-2011

US health care major Abbott Laboratories (NYSE: ABT) has entered into a second mega-million dollar licensing…

Abbott LaboratoriesAnti-Arthritics/RheumaticsbardoxoloneBiotechnologyLicensingNeurologicalPharmaceuticalReata Pharmaceuticals

Biogen Idec in up to $553 million deal with Portola for oral Syk inhibitor program

28-10-2011

USA-based Biogen Idec (Nasdaq: BIIB) and Portola Pharmaceutical have entered into an exclusive, worldwide…

Anti-Arthritics/RheumaticsBiogen IdecBiotechnologyLicensingPharmaceuticalPortola PharmaceuticalsRare diseasesResearch

Back to top